New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTEBSEmergent BioSolutions sees FY13 revenue $311M-$313M, consensus $307.84M.
The company also anticipates FY13 GAAP net income of $30M-$32M. Excluding approximately $7M of transaction-related and restructuring costs incurred during the year, the company is providing a forecast for 2013 non-GAAP adjusted net income of $35M-$37M.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
17:33 EDTEBSEmergent BioSolutions, MorphoSys sign license agreement for ES414
Subscribe for More Information
August 7, 2014
16:23 EDTEBSEmergent BioSolutions sees Q3 revenue $110M-$125M, consensus $125.17M
Subscribe for More Information
16:22 EDTEBSEmergent BioSolutions raises FY14 revenue view to $425-$450M from $415M-$445M
Subscribe for More Information
16:20 EDTEBSEmergent BioSol' reports Q2 GAAP EPS 13c, may not compare with consensus 32c
Reports Q2 revenue $110.3M, consensus $109.25M.
07:13 EDTEBSEmergent BioSolutions submits BLA to FDA for AIGIV
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use